Sanofi closes $9.1B acquisition of Blueprint Medicines; shares delisted

Blueprint Medicines Corp

Purchaser accepted 45,991,262 shares (70.9% of outstanding) at $129/share cash plus one CVR per share.
Aggregate consideration ~$9.1B in cash plus CVRs with potential up to $6/share contingent on milestones.
All directors resigned; Michael J. Tolpa became sole director; Blueprint now indirect Sanofi subsidiary.
Shares no longer listed on Nasdaq; company will file Form 15 to suspend SEC reporting obligations.
Previously disclosed stockholder litigation (Taylor action) resolved with $150,000 mootness fee; case closed.

item 1.02item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.